Total, bioavailable and free 25-hydroxyvitamin D are associated with the prognosis of patients with non-small cell lung cancer

Si-Min Peng1 · Na Yu2 · Jun Che3 · Jia-Ying Xu4 · Guo-Chong Chen1 · Da-Peng Li5 · Yu-Song Zhang2 · Li-Qiang Qin1

Received: 10 January 2022 / Accepted: 26 March 2022 / Published online: 11 April 2022
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022

Abstract

Purpose To analyze the prognostic value of total, bioavailable and free 25-hydroxyvitamin D [25(OH)D] as well as vitamin D-binding protein (VDBP) in patients with non-small cell lung cancer (NSCLC).

Methods We prospectively collected and analyzed data for 395 patients diagnosed with NSCLC between January 2016 and December 2018 in two university-affiliated hospitals. Total and free 25(OH)D and VDBP were measured directly, and bioavailable 25(OH)D was calculated using a validated formula. Their prognostic values were evaluated by Cox proportional hazards model, and hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated.

Results Patients with NSCLC had significantly lower levels of total, bioavailable, and free 25(OH)D and higher VDBP levels in comparison to healthy controls (all \( p < 0.001 \)). In multivariate analyses, higher levels of total, bioavailable, and free 25(OH)D were independently associated better overall survival (OS) and progression-free survival (PFS). For OS, the adjusted HRs were 0.58 (95% CI, 0.40–0.87; \( p \) for trend = 0.008), 0.45 (95% CI, 0.30–0.67; \( p \) for trend < 0.001) and 0.49 (95% CI, 0.33–0.73; \( p \) for trend < 0.001) for the highest versus the lowest tertile of total, bioavailable and free 25(OH)D, respectively. The corresponding adjusted HRs for PFS were 0.61 (95% CI, 0.43–0.86; \( p \) for trend = 0.006), 0.56 (95% CI, 0.40–0.80; \( p \) for trend = 0.001) and 0.60 (95% CI, 0.42–0.85; \( p \) for trend = 0.004), respectively. However, VDBP was not associated with either OS or PFS.

Conclusion The current study suggested that total, bioavailable and free 25(OH)D may be reliable prognosis indicators in NSCLC patients, though the optimal 25(OH)D form for NSCLC prognosis remains to be assessed in future studies.

Keywords Vitamin D · Vitamin D-binding protein · Bioavailability · Survival · NSCLC

Introduction

Lung cancer is the second most common cancer with the highest mortality rate worldwide [1]. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer [2]. Although a wide range of treatments have been clinically available [3], the prognosis remains poor, with a 5-year survival rate of 19.8% in China [4]. It is of great clinical significance to explore valuable and adequate prognostic indicators to further guide individualized disease management in NSCLC.

Vitamin D, traditionally known as an essential nutrient, is a precursor of a potent steroid hormone that regulates a broad spectrum of physiological processes [5]. Increasing evidence indicates a significant anti-tumor effect of vitamin D through inhibiting cell proliferation, angiogenesis, and metastasis, while inducing apoptosis and differentiation [6]. However, vitamin D deficiency is evident globally...
and even more severe in cancer patients, including patients with lung cancer [7, 8]. Low levels of circulating vitamin D concentrations have been associated with poorer survival in NSCLC, but the findings are inconsistent [9–13].

As the major vitamin D circulating form in the human organism, total serum or plasma 25-hydroxyvitamin D [25(OH)D] is currently routinely used in clinical practice to assess vitamin D status [14]. About 85–90% of total 25(OH)D circulates bound to vitamin D-binding protein (VDBP), and this proportion is recognized as the biologically inactive form. The non-VDBP-bound fraction, consisting primarily of albumin-bound 25(OH)D (10–15%) and less than 0.03% of total 25(OH)D in the free form, is considered as bioavailable 25(OH)D. The free and albumin (with a 1,000-fold weaker affinity for 25(OH)D than VDBP) forms are easier to be taken up by cell tissues, thereby exerting its biological actions [15]. Recent studies have reported that bioavailable or free 25(OH)D may be more representative indicators for vitamin D status as compared with total 25(OH)D [16, 17]. Current studies on vitamin D and lung cancer have been focused on total 25(OH)D and, to our knowledge, the relationships between circulating bioavailable and free 25(OH)D levels and prognosis of NSCLC are yet to be assessed.

In addition, VDBP may influence cancer progression in addition to being a carrier for vitamin D metabolites [18]. Therefore, we aimed to investigate the associations of total, bioavailable, and free 25(OH)D and VDBP with survival in NSCLC patients.

Methods

Study population

The Soochow Lung Cancer Cohort (SLCC) study is an ongoing patient cohort conducted in the first affiliated hospital and the second affiliated hospital of Soochow University. This study was designed to investigate the long-term prognosis factors among lung cancer patients in Southeast China. As described previously [19], a total of 525 primary lung cancer patients aged ≥18 years were enrolled in the cohort between January 2016 and December 2018. For the current study, we excluded patients with small cell lung cancer (n = 62). We further excluded patients lost to follow-up (n = 29) and those with no sufficient data (n = 39). Finally, the current study included 395 NSCLC patients. To compare the vitamin D indices with controls, 50 healthy volunteers (25 men and 25 women with a mean age of 60 years) were enrolled by Suzhou Industrial Park Centers for Disease Control and Prevention in October 2020.

Data collection

An in-person interview was conducted by trained investigators using a structured questionnaire within 1 week after diagnosis to collect general information about age, gender, disease history [e.g., chronic obstructive pulmonary disease (COPD)], family history of cancer, body mass index (BMI), in addition to behavioral factors such as smoking status and alcohol consumption. Participants were asked to recall the frequency of alcohol consumption during the year prior to the baseline assessment. According to the obtained information, smoking status was categorized as never, former, or current smoker. Current smokers were defined as patients who had smoked continuously or accumulated for at least 6 months and continued to smoke during the baseline survey or those quitting smoking for less than 1 year. Former smokers were defined as those who had quit smoking for more than 1 year at the study entry. Furthermore, medical records were also reviewed to extract their clinical data, including cancer characteristics (TNM stage, histology, lesion and laterality), treatments (surgery, chemotherapy, radiotherapy and targeted therapy), and the levels of various blood analytes. Blood analytes included albumin, total cholesterol, neutrophils, lymphocytes, monocytes, carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE). Neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) were calculated based on the collected data.

Determination of 25(OH)D fractions and VDBP

A fasting plasma sample was collected from each patient at the time of recruitment. All samples were numbered and stored at −80 °C until further analysis. The plasma circulating total 25(OH)D (D2 and D3) levels were measured with the use of liquid chromatography-mass spectrometry (LC–MS/MS) at Suzhou Harmony Health Medical Laboratory Co., Ltd. The mean intra-assay coefficient of variation (CV) was 1.7%. VDBP and free 25(OH)D were measured by commercial enzyme-linked immunosorbent (ELISA) assays (R&D Systems, Minneapolis, MN, USA and DIAsource ImmunoAssays, Louvainla-Neuve, Belgium, respectively). The mean CV values were 5.3% and 6.1% for VDBP and free 25(OH)D, respectively. Bioavailable 25(OH)D (Bio D) was calculated from measured free 25(OH)D, albumin, and affinity constant between 25(OH)D and albumin using the following formula [16]:

\[ [\text{Bio } D] = [\text{D}_{\text{Free}}] + [\text{D}_{\text{Alb}}] = (K_{\text{Alb}}[\text{Alb}]+1)[\text{D}_{\text{Free}}], \]

where \([\text{D}_{\text{free}}]\) is the concentration of free 25(OH)D, \([\text{D}_{\text{Alb}}]\) is the concentration of albumin-bound 25(OH)D, [Alb] is the concentration of serum albumin, and Kalb is the affinity constant between 25(OH)D and albumin (6 × 10³ M⁻¹).
Results

Baseline clinical characteristics

Of the 395 NSCLC patients included in the study, the mean age was 63.0 ± 10.5 years, and 63.8% of the participants were men. 49.4% were former/current smokers and 65.1% were classified as stage IIIB–IV (Table 1). The associations between baseline clinical characteristics and total 25(OH)D are summarized in Table 1. Patients with higher total 25(OH)D levels had higher levels of albumin and LMR, and were more likely to be collected for the blood samples in spring and autumn and to receive surgery or chemotherapy. Meanwhile, patients with higher bioavailable 25(OH)D levels had higher levels of BMI, albumin and LMR. Additionally, both bioavailable and free 25(OH)D were associated with the season of blood-drawing (Supplementary Table 1).

Plasma levels of 25(OH)D Fractions and VDBP in NSCLC patients

Plasma levels of total, bioavailable, and free 25(OH)D and VDBP in control group and NSCLC patient group are presented in Fig. 1. Mean total 25(OH)D concentration was 20.78 ± 7.81 ng/mL for all NSCLC patients. According to the reference ranges of clinical practice guideline [20], 37% of the patients were considered to be 25(OH)D insufficient (20 to 30 ng/mL) and 50.1% were deficient (<20 ng/mL). Compared with healthy controls, NSCLC patients had significantly lower levels of total, bioavailable and free 25(OH)D (25.56 ± 8.75 vs. 20.78 ± 7.81 ng/mL, 5.82 ± 1.06 vs. 2.87 ± 1.35 ng/mL, and 16.13 ± 1.82 vs. 7.69 ± 3.41 pg/mL, respectively, all p < 0.001), while had higher VDBP levels (175.69 ± 35.24 vs. 204.93 ± 50.47 μg/mL, p < 0.001). Meanwhile, NSCLC survivors had significantly higher total, bioavailable and free 25(OH)D levels than non-survivors (all p < 0.001). However, no significant differences in VDBP levels were observed between survivors and non-survivors. All blood samples of the healthy controls were collected in Autumn. In order to minimize the influence of seasonal differences, the levels of 25(OH)D fractions and VDBP for the healthy controls were further compared with the patients enrolled in autumn, and the results were similar to the original findings involving all patients (Supplementary Fig. 1).

Follow-up

Follow-up of patient outcomes began at the date of enrollment until the last follow-up date (December 2020) or until the date of death. The survival outcomes were evaluated semiannually. Information sources included the hospital inpatient or outpatient records, patient or family telephonic contact, in addition to local death registration system. Overall survival (OS) was defined as the time from the date of enrollment to the date of death, and progression-free survival (PFS) was defined as the time from the date of enrollment to the date of confirmed progressive disease (PD) or death.

Statistical analysis

The 25(OH)D fractions (total, bioavailable, and free) and VDBP levels were categorized into three groups by the tertiles of the variables, and the Spearman correlation test was used to test their pairwise associations. One-way analysis of variance (ANOVA) with Tukey’s Honestly Significant Difference (HSD) pairwise comparisons were used to evaluate the differences of the 25(OH)D fractions and VDBP levels among normal group, NSCLC survivors, and NSCLC non-survivors. The receiver operating characteristic (ROC) curve was used to determine the optimal cutoff value of the NLR and LMR. The chi-square test or Fisher’s exact test was applied to explore differences in categorical variables. The Kaplan–Meier method with log-rank test was used to construct survival curves. Univariate and multivariate Cox proportional hazards regression models were used to identify variables associated with OS and PFS. Hazard ratios (HR) and 95% confidence intervals (CI) were then calculated for variables associated with OS and PFS. Baseline variables that were considered clinically relevant or that showed a univariate relationship with outcome were entered into multivariate analyses. In order to reduce the impact of lifestyle alteration for the outcomes, additional sensitivity analysis was performed after excluding patients who were deceased in the first 6 months of the follow-up. p values for the linear trends were calculated by entering the median values for each tertile of 25(OH)D or VDBP into the models as a continuous variable. Further stratified multivariate analyses were performed according to age, gender, smoking, TNM stage, histology, lesion and surgery, while we also recognized that these analyses are subject to limited statistical power. Interactions were evaluated using the Wald test. Time-dependent ROC curves for the prognostic values of 25(OH)D fractions and VDBP were estimated using the R package survivalROC. All analyses were performed by IBM SPSS 25.0 and R software version 3.6.3. Two-sided p value < 0.05 was considered statistically significant.
Table 1  The relationship between total 25(OH)D and clinical characteristics in NSCLC patients [n (%)]

| Variable                          | Category                  | Total 25(OH)D | p value |
|-----------------------------------|---------------------------|---------------|---------|
|                                   |                           | Tertile 1 (n=132) | Tertile 2 (n=132) | Tertile 3 (n=131) |
| Mean ± SD (ng/mL)                 |                           | 12.55 ± 2.92   | 20.14 ± 2.23   | 29.73 ± 4.62   |
| Age (years)                       | < 65                      | 62 (47.0)      | 72 (54.5)      | 71 (54.2)      | 0.380 |
|                                   | ≥ 65                      | 70 (53.0)      | 60 (45.5)      | 60 (45.8)      |       |
| Gender                            | Male                      | 84 (63.6)      | 88 (66.7)      | 80 (61.1)      | 0.639 |
|                                   | Female                    | 48 (36.4)      | 44 (33.3)      | 51 (38.9)      |       |
| Smoking                           | Never                     | 67 (50.8)      | 65 (49.2)      | 68 (51.9)      | 0.910 |
|                                   | Former/current            | 65 (49.2)      | 67 (50.8)      | 63 (48.1)      |       |
| Drinking                          | Yes                       | 24 (18.2)      | 31 (23.5)      | 29 (22.1)      | 0.550 |
|                                   | No                        | 108 (81.8)     | 101 (76.5)     | 102 (77.9)     |       |
| COPD                              | Yes                       | 7 (5.3)        | 4 (3.0)        | 6 (4.6)        | 0.649 |
|                                   | No                        | 125 (94.7)     | 128 (97.0)     | 125 (95.4)     |       |
| Family history of cancer          | Yes                       | 16 (12.1)      | 23 (17.4)      | 23 (17.6)      | 0.384 |
|                                   | No                        | 116 (87.9)     | 109 (82.6)     | 108 (82.4)     |       |
| BMI (kg/m²)                       | < 18.5                    | 12 (9.1)       | 11 (8.3)       | 11 (8.4)       | 0.154 |
|                                   | 18.5–24                   | 94 (71.2)      | 87 (65.9)      | 76 (58.0)      |       |
|                                   | ≥ 24                      | 26 (19.7)      | 34 (25.8)      | 44 (33.6)      |       |
| Season of blood-drawing           | Spring                    | 74 (56.1)      | 56 (42.4)      | 51 (38.9)      | 0.030 |
|                                   | Summer                    | 16 (12.1)      | 24 (18.2)      | 20 (15.3)      |       |
|                                   | Autumn                    | 23 (17.4)      | 35 (26.5)      | 45 (34.4)      |       |
|                                   | Winter                    | 19 (14.4)      | 17 (12.9)      | 15 (11.5)      |       |
| TNM stage                         | I-IIIA                    | 41 (31.1)      | 43 (32.6)      | 54 (41.2)      | 0.176 |
|                                   | IIIB-IV                   | 91 (68.9)      | 89 (67.4)      | 77 (58.8)      |       |
| Histology                         | AC                        | 87 (65.9)      | 94 (71.2)      | 99 (75.6)      | 0.309 |
|                                   | SCC                       | 41 (31.1)      | 31 (23.5)      | 27 (20.6)      |       |
|                                   | Others                    | 4 (3.0)        | 7 (5.3)        | 5 (3.8)        |       |
| Lesion                            | Central                   | 51 (38.6)      | 46 (34.8)      | 40 (30.5)      | 0.385 |
|                                   | Peripheral                | 81 (61.4)      | 86 (65.2)      | 91 (69.5)      |       |
| Laterality                        | Left                      | 63 (47.7)      | 62 (47.0)      | 46 (35.1)      | 0.069 |
|                                   | Right                     | 69 (52.3)      | 70 (53.0)      | 85 (64.9)      |       |
| Surgery                           | Yes                       | 53 (40.2)      | 71 (53.8)      | 75 (57.3)      | 0.012 |
|                                   | No                        | 79 (59.8)      | 61 (46.2)      | 56 (42.7)      |       |
| Chemotherapy                      | Yes                       | 100 (75.8)     | 119 (90.2)     | 110 (84.0)     | 0.007 |
|                                   | No                        | 32 (24.2)      | 13 (9.8)       | 21 (16.0)      |       |
| Radiotherapy                      | Yes                       | 27 (20.5)      | 20 (15.2)      | 21 (16.0)      | 0.473 |
|                                   | No                        | 105 (79.5)     | 112 (84.8)     | 110 (84.0)     |       |
| Targeted therapy                  | Yes                       | 45 (34.1)      | 34 (25.8)      | 32 (24.4)      | 0.167 |
|                                   | No                        | 87 (65.9)      | 98 (74.2)      | 99 (75.6)      |       |
| CEA (ng/mL)                       | < 6.5                     | 77 (58.3)      | 86 (65.2)      | 81 (61.8)      | 0.522 |
|                                   | ≥ 6.5                     | 55 (41.7)      | 46 (34.8)      | 50 (38.2)      |       |
| NSE (ng/mL)                       | < 17                      | 98 (74.2)      | 104 (87.8)     | 110 (84.0)     | 0.153 |
|                                   | ≥ 17                      | 34 (25.8)      | 28 (21.2)      | 21 (16.0)      |       |
| Albumin (g/L)                     | < 40                      | 58 (43.9)      | 40 (30.3)      | 38 (29.0)      | 0.018 |
|                                   | ≥ 40                      | 74 (56.1)      | 92 (69.7)      | 93 (71.0)      |       |
| Total cholesterol (mg/dL)         | ≤ 180                     | 76 (57.6)      | 63 (47.7)      | 66 (50.4)      | 0.253 |
|                                   | > 180                     | 56 (42.4)      | 69 (52.3)      | 65 (49.6)      |       |
| NLR                               | ≤ 2.63                    | 55 (41.7)      | 67 (50.8)      | 66 (50.4)      | 0.247 |
|                                   | > 2.63                    | 77 (58.3)      | 65 (49.2)      | 65 (49.6)      |       |
| LMR                               | ≤ 3.17                    | 84 (63.6)      | 60 (45.5)      | 65 (49.6)      | 0.008 |
|                                   | > 3.17                    | 48 (36.4)      | 72 (54.5)      | 66 (50.4)      |       |

25(OH)D 25-hydroxyvitamin D, AC adenocarcinoma, BMI body Mass Index, CEA carcinoembryonic antigen, COPD chronic obstructive pulmonary emphysema, LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, NSE neuron-specific enolase, SD standard deviation, SCC squamous cell carcinoma
Impacts of 25(OH)D fractions and VDBP on survival

During a median 32 months (range: 1 to 60 months) of follow-up period, 179 (45.3%) patient deaths occurred. The Kaplan–Meier analysis showed that NSCLC patients with higher total 25(OH)D levels had better OS ($p < 0.001$, log-rank test) and PFS ($p < 0.001$, log-rank test) (Fig. 2A, B). Similarly, higher bioavailable and free 25(OH)D levels were associated with significantly increased OS ($p < 0.001$ for bioavailable and $p = 0.002$ for free 25(OH)D, log-rank test).
test) and PFS ($p < 0.001$ for bioavailable and $p = 0.001$ for free 25(OH)D, log-rank test) (Fig. 2C–F). However, there were no significant associations between VDBP and survival outcomes ($p = 0.610$ for OS and $p = 0.470$ for PFS, log-rank test; Fig. 2G–H).

Then, we further explored the association between 25(OH)D fractions or VDBP and survival through Cox regression analyses. Univariate analyses suggested that gender, smoking, drinking, COPD, BMI, season of blood-drawing, TNM stage, histology, surgery, CEA, NSE, albumin, total cholesterol, NLR and LMR were significant prognostic factors for OS (all $p < 0.2$; Supplementary Table 2). And in addition to the factors mentioned above, radiotherapy and targeted therapy were also significant prognostic factors for PFS (all $p < 0.2$; Supplementary Table 2). Furthermore, age was considered as an important factor due to its clinical relevance.

All three 25(OH)D fractions were identified as independent prognostic indicators for survival after adjustment for factors mentioned above. The multivariable-adjusted HRs for the highest versus the lowest tertile of total 25(OH)D levels were $0.58$ (95% CI, 0.40–0.87; $p$ for trend = 0.008) for OS and $0.61$ (95% CI, 0.43–0.86; $p$ for trend = 0.006) for PFS. Meanwhile, the multivariable-adjusted HRs for the highest versus the lowest tertile of bioavailable 25(OH)D levels were $0.45$ (95% CI, 0.30–0.67; $p$ for trend < 0.001) for OS and $0.56$ (95% CI, 0.40–0.80; $p$ for trend = 0.001) for PFS. And the multivariable-adjusted HRs for the highest versus the lowest tertile of free 25(OH)D levels were $0.49$ (95% CI, 0.33–0.73; $p$ for trend < 0.001) for OS and $0.60$ (95% CI, 0.42–0.85; $p$ for trend = 0.004) for PFS. However, VDBP were not significantly associated with either OS or PFS (both $p$ for trend > 0.05; Table 3). Lifestyle alteration (e.g., reduced outdoor activities) after diagnosis may lead to a decrease in vitamin D levels (especially so for the patients with very poor health status), thus affecting the outcomes. Therefore, in order to reduce the impact of lifestyle alteration, an additional sensitivity analysis was performed through excluding patients who died in the first 6 months of follow-up. It showed that high levels of three 25(OH)D fractions were still independently associated with improved survival (Supplementary Table 3).

We found that the inverse association of total, bioavailable, and free 25(OH)D with OS or PFS rate remained in most of the predefined subgroups, despite reduced statistical power in these analyses. And there were no statistical interactions between the three 25(OH)D fractions and any of the above clinical characteristics (All $p$ for interaction > 0.05; Supplementary Tables 4–6).

**Prognostic performance of 25(OH)D fractions and VDBP**

As shown in Fig. 3, we compared the prognostic performance of the total, bioavailable, free 25(OH)D and VDBP. The time-dependent ROC curves showed that bioavailable and total 25(OH)D obtained similar AUCs in dynamic trends within the follow-up time. In addition, the time-dependent

Fig. 2 Kaplan–Meier survival curves for overall survival (OS) (A) and progression-free survival (PFS) (B) by tertiles of total 25(OH)D levels, for OS (C) and PFS (D) by tertiles of bioavailable 25(OH)D levels, for OS (E) and PFS (F) by tertiles of free 25(OH)D levels, and for OS (G) and PFS (H) by tertiles of vitamin D-binding protein levels.
### Table 3 Hazard ratios for survival by tertile of plasma total, bioavailable and free 25(OH)D and VDBP in NSCLC patients

|                | Tertile 1 | Tertile 2 | Tertile 3 | p for trend |
|----------------|-----------|-----------|-----------|-------------|
| **OS**         |           |           |           |             |
| Total 25(OH)D  |           |           |           |             |
| Cut points (ng/mL) | ≤ 16.41   | 16.42–23.94 | > 23.95 |             |
| Event/total cases | 77/132    | 58/132    | 44/131    |             |
| Unadjusted HR (95% CI) | 1 0.63 (0.45–0.89) | 0.48 (0.33–0.70) | < 0.001   |             |
| Multivariable-adjusted HR (95% CI)a | 1 0.83 (0.57–1.21) | 0.58 (0.40–0.87) | 0.008     |             |
| Bioavailable 25(OH)D |           |           |           |             |
| Cut points (ng/mL) | ≤ 2.21    | 2.22–3.40 | > 3.41    |             |
| Event/total cases | 76/132    | 60/132    | 43/131    |             |
| Unadjusted HR (95% CI) | 1 0.73 (0.52–1.02) | 0.43 (0.30–0.63) | < 0.001   |             |
| Multivariable-adjusted HR (95% CI)a | 1 0.63 (0.43–0.92) | 0.45 (0.30–0.67) | < 0.001   |             |
| Free 25(OH)D    |           |           |           |             |
| Cut points (pg/mL) | ≤ 6.04    | 6.05–9.12 | > 9.13    |             |
| Event/total cases | 73/132    | 61/132    | 45/131    |             |
| Unadjusted HR (95% CI) | 1 0.78 (0.56–1.10) | 0.53 (0.36–0.77) | 0.001     |             |
| Multivariable-adjusted HR (95% CI)a | 1 0.68 (0.47–1.00) | 0.49 (0.33–0.73) | < 0.001   |             |
| VDBP            |           |           |           |             |
| Cut points (μg/mL) | ≤ 181.49  | 181.50–222.71 | > 222.72 |             |
| Event/total cases | 64/132    | 55/132    | 60/131    |             |
| Unadjusted HR (95% CI) | 1 0.86 (0.60–1.23) | 1.00 (0.70–1.42) | 0.966     |             |
| Multivariable-adjusted HR (95% CI)a | 1 0.67 (0.46–0.99) | 0.74 (0.51–1.08) | 0.114     |             |
| **PFS**         |           |           |           |             |
| Total 25(OH)D  |           |           |           |             |
| Cut points (ng/mL) | ≤ 16.41   | 16.42–23.94 | > 23.95 |             |
| Event/total cases | 94/132    | 71/132    | 62/131    |             |
| Unadjusted HR (95% CI) | 1 0.56 (0.41–0.77) | 0.48 (0.35–0.67) | < 0.001   |             |
| Multivariable-adjusted HR (95% CI)b | 1 0.69 (0.49–0.98) | 0.61 (0.43–0.86) | 0.006     |             |
| Bioavailable 25(OH)D |           |           |           |             |
| Cut points (ng/mL) | ≤ 2.21    | 2.22–3.40 | > 3.41    |             |
| Event/total cases | 89/132    | 77/132    | 61/131    |             |
| Unadjusted HR (95% CI) | 1 0.80 (0.59–1.08) | 0.53 (0.38–0.73) | < 0.001   |             |
| Multivariable-adjusted HR (95% CI)b | 1 0.79 (0.56–1.10) | 0.56 (0.40–0.80) | 0.001     |             |
| Free 25(OH)D    |           |           |           |             |
| Cut points (pg/mL) | ≤ 6.04    | 6.05–9.12 | > 9.13    |             |
| Event/total cases | 85/132    | 78/132    | 64/131    |             |
| Unadjusted HR (95% CI) | 1 0.85 (0.62–1.15) | 0.64 (0.46–0.88) | 0.007     |             |
| Multivariable-adjusted HR (95% CI)b | 1 0.74 (0.52–1.05) | 0.60 (0.42–0.85) | 0.004     |             |
| VDBP            |           |           |           |             |
| Cut points (μg/mL) | ≤ 181.49  | 181.50–222.71 | > 222.72 |             |
| Event/total cases | 78/132    | 73/132    | 76/131    |             |
| Unadjusted HR (95% CI) | 1 0.87 (0.64–1.20) | 0.96 (0.70–1.32) | 0.780     |             |
| Multivariable-adjusted HR (95% CI)b | 1 0.73 (0.52–1.02) | 0.84 (0.60–1.17) | 0.290     |             |

25(OH)D 25-hydroxyvitamin D, CI confidence intervals, HR hazard ratio, OS overall survival, PFS progression-free survival, VDBP vitamin D-binding protein

a Adjusted for age, gender, smoking, drinking, COPD, BMI, season of blood-drawing, TNM stage, histology, surgery, CEA, NSE, albumin, total cholesterol, NLR and LMR

b Adjusted additionally for radiotherapy and targeted therapy
ROC curves of bioavailable and total 25(OH)D were slightly higher than that of free 25(OH)D, but the difference was not significant. However, the AUCs of VDBP was significantly lower than that of 25(OH)D fractions. The AUC of the total, bioavailable, free 25(OH)D and VDBP for predicting 3-year OS were 0.636, 0.620, 0.594 and 0.499, respectively, while the corresponding AUCs for predicting 3-year PFS were 0.642, 0.620, 0.595 and 0.503, respectively.

Discussion

In this study, we evaluated the potential importance of total, bioavailable and free 25(OH)D as well as VDBP as pre-treatment prognostic indicators for OS and PFS among patients with NSCLC. We found that all three 25(OH)D fractions had discrimination for long-term survival in NSCLC patients, as high levels of total, bioavailable and free 25(OH)D each were associated with better OS and PFS. But we did not find a superior prognostic performance in bioavailable or free 25(OH)D as compared to total 25(OH)D. Moreover, no significant association was found between VDBP and survival in NSCLC.

Vitamin D deficiency is common in cancer patients, including patients with lung cancer. Herein, we found that 50.1% of the patients had vitamin D deficiency [25(OH)D level < 20 ng/mL] and 37.0% had insufficiency (20–30 ng/mL), suggesting a severe vitamin D deficiency status in the current NSCLC cohort, which is consistent with previous studies [11, 21]. In addition, compared with healthy controls, total 25(OH)D was lower in NSCLC patients, among whom survivors had a higher level of total 25(OH)D than non-survivors, indicating a latent impact of vitamin D on the disease prognosis of NSCLC.

Various mechanisms may underlie the influence of vitamin D on the progression and prognosis of lung cancer. Vitamin D can inhibit lung cancer tumor growth, migration and proliferation, and promote apoptosis by downregulating Histidine-rich calcium-binding protein (HRC) [22]. As an active metabolite of vitamin D, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] induces E-cadherin and decreases EMT-related molecules SNAIL, ZEB1, and vimentin in NSCLC cells, thus preventing NSCLC progression [23]. Besides, vitamin D deficiency may increase inflammation and proliferation of pre-malignant cells thereby enhancing progression of squamous lesions [24]. By contrast, vitamin D treatment in the EGFR mutant NSCLC cells may lead to an inhibition of clonogenic growth in a dose-dependent manner [25]. And vitamin D or vitamin D derivatives play a powerful synergic role when used in combination with chemotherapy drugs, promoting the cytotoxic effects of drugs and reducing drug resistance on NSCLC cells compared to using the free single drug [26, 27].

Given the close affinity of vitamin D and NSCLC, the prognostic impact of vitamin D levels on NSCLC has been investigated previously, but the results are controversial. Several cohort studies addressed that higher pre-treatment circulating 25(OH)D showed an association with improved survival of patients with early- or advanced-stage NSCLC [9–11]. In contrast, two other studies demonstrated that 25(OH)D levels at the time of initial diagnosis or before treatment had no effect on survival in advanced NSCLC [12, 13]. In addition, a nested case–control study suggested that higher 25(OH)D was associated with significantly better
survival among patients with lung adenocarcinoma but not among those with squamous cell carcinoma [28]. The inconsistent findings indicate that the role of vitamin D in NSCLC prognosis still deserves further exploration.

Recent studies have highlighted bioavailable or free 25(OH)D as a more meaningful marker of vitamin D function [16, 17]. In the current study, besides total 25(OH)D, we measured bioavailable and free 25(OH)D levels and investigated their relationships with NSCLC prognosis for the first time. We found that plasma concentrations of bioavailable and free 25(OH)D both were significantly decreased as compared to healthy controls. Additionally, total 25(OH)D was positively associated with both bioavailable and free 25(OH)D, which may partly explain the decrement of bioavailable and free 25(OH)D. We also found that total, bioavailable, and free 25(OH)D levels were inversely related to both OS and PFS, indicating all three 25(OH)D forms as independent predictors for survival among NSCLC patients. Besides, the AUCs for bioavailable and free 25(OH)D were similar to that for total 25(OH)D in dynamic trend, thus we could not distinguish if bioavailable and free 25(OH)D were superior to total 25(OH)D in predicting NSCLC prognosis.

Our results did not completely correspond with finding for other cancers in previous studies. Chen et al. reported that plasma bioavailable 25(OH)D was independently associated with PFS and OS, while total 25(OH)D was independently associated with PFS but not OS in diffuse large B-cell lymphoma [29]. Yang et al. showed that higher bioavailable and free 25(OH)D, rather than total 25(OH)D, were associated with better OS in I–III stage colorectal cancer, though only free 25(OH)D was an independent prognostic factor for OS [30]. Similarly, Fang et al. suggested that bioavailable 25(OH)D was a preferable biomarker over total 25(OH)D for the prognosis of hepatocellular carcinoma [31]. By contrast, Yuan et al. demonstrated that bioavailable 25(OH)D levels were not more strongly associated with risk of advanced and lethal prostate cancer than total 25(OH)D levels [32]. There are several potential reasons for the inconsistent findings for different cancers. First, the measurements for 25(OH)D fractions varied across these studies, and there is no uniform standard measurement or cutoff value for bioavailable and free 25(OH)D at present. Second, circulating vitamin D concentration may be influenced by various factors such as liver function, kidney diseases, estrogens and genetic background [15], thus 25(OH)D fractions measured at a single time point in these studies may not comprehensively represent the overall vitamin D status of the enrolled patients. And finally, total 25(OH)D levels may indeed differ in distinct cancers. The mean level of total 25(OH)D in Fang et al. study was much higher than the levels in Chen et al. and in our present study (35.8 ng/mL vs. 16.0–20.8 ng/mL) [29, 31]. It is possible that total 25(OH)D with a small increment provides more benefit for patients with vitamin D deficiency (< 20 ng/mL), but no meaningful impact on patients with sufficient vitamin D (> 30 ng/mL). Taken together, high level of vitamin D may have a positive association with improved prognosis in various cancers. However, it still should be more prudent about the conclusion that bioavailable or free 25(OH)D could be a better biomarker for the estimation of vitamin D status or the prediction of cancer prognosis.

In addition to different forms of vitamin D, another important biomarker for vitamin D status is VDBP. We found that VDBP levels were significantly higher in NSCLC patients compared with healthy controls. As VDBP is bound to most of vitamin D, the increase of its levels may reduce the free or bioavailable fractions of vitamin D. In other words, the bioavailability of vitamin D may be limited even though circulating vitamin D is sufficient. Previous studies showed an inverse association between VDBP and free or bioavailable 25(OH)D [32, 33], though the association was not confirmed in the current study. Furthermore, VDBP per se has multiple biological activities beyond vitamin D transporter, including extracellular actin scavenger and enhancement of neutrophil chemotactic activity [18]. Particularly, the VDBP-derived macrophage activating factor (MAF) demonstrated potent inhibition of both proliferation and migration of tumor cells [34], and induced tumor cells apoptosis through stimulating macrophages [35]. To date, two studies have examined the relationship between VDBP level and lung cancer prognosis. One UK study including 148 NSCLC patients showed that patients with the highest quartile of VDBP (> 430.2 μg/mL) tended to have better prognosis in comparison to those with the lowest quartile of VDBP (< 199.4 μg/mL) [36]. The other study conducted in 500 Finnish male lung cancer cases demonstrated that circulating concentration of VDBP was not associated with lung cancer specific survival [28]. In the current study, no significant association was found between VDBP level and OS [37] and NSCLC survival. Of note, VDBP in the European studies are much higher than that in our study (291–337 μg/mL vs. 204.9 μg/mL), which might be partially attributed to the differences in race and genetic polymorphisms [16]. Whether a sufficiently high level of VDBP (such as > 430.2 μg/mL) may have a positive effect on the progression of lung cancer remains to be further investigated.

Several limitations to our study should be acknowledged. First, the sample size was relatively small, thus the findings of the present study may need to be generalized with caution, and further studies with larger sample sizes are needed to precisely validate these results. Second, the bioavailable 25(OH)D level was calculated based on the total 25(OH)D level, albumin level, and VDBP level in the plasma. The direct measurement of the bioavailable 25(OH)D level was established recently [37] and could be used in future studies. Thirdly, the concentrations of 25(OH)D and VDBP were measured only once but not dynamically, and it remains
unknown whether temporal changes in 25(OH)D and VDBP have significant effect on the prognosis of NSCLC patients. Finally, other factors affecting vitamin D levels, such as physical activity, sunlight exposure and vitamin D supplementation, were not evaluated in our study. But season of blood-drawing was included as a potential confounder factor, which may reflect sunlight exposure partially. Nevertheless, this study also has several strengths, including the prospective design to minimize the potential for reverse causality. Furthermore, to the best of our knowledge, this is the first study to explore of the relationship between bioavailable and free 25(OH)D and NSCLC survival.

Conclusion

In summary, total, bioavailable, and free 25(OH)D may serve as reliable biomarkers in predicting the OS and PFS of NSCLC patients. And further studies are needed to validate our findings in larger and different patient populations.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10552-022-01579-6.

Funding This work was supported by the project of State key laboratory of radiation medicine and protection (GZK1202007); the second affiliate hospital of Soochow university science and technology innovation team project funding (XKTJ-TD202009); and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

Data availability All datasets generated for this manuscript can be obtained from the corresponding author on reasonable request.

Declarations

Conflict of interest The authors declare no conflict of interest.

Ethical approval This study was approved by the Research Ethics Committee of Soochow University (Approval No. ESCU-2015-0002). All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent Written informed consent was obtained from all participants.

References

1. Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249
2. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367–1380
3. Hirsch FR, Scagliotti GV, Mulshine JL et al (2017) Lung cancer: current therapies and new targeted treatments. Lancet 389:299–311
4. Allemani C, Matsuda T, Di Carlo V et al (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3); analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391:1023–1075
5. Hossein-nezhad A, Holick MF (2013) Vitamin D for health: a global perspective. Mayo Clin Proc 88:720–755
6. Jeon S-M, Shin E-A (2018) Exploring vitamin D metabolism and function in cancer. Exp Mol Med 50:1–14
7. Amrein K, Scherkl M, Hoffmann M et al (2020) Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr 74:1498–1513
8. Aguirre M, Manzano N, Salas Y, Angel M, Díaz-Couselo FA, Zylberman M (2016) Vitamin D deficiency in patients admitted to the general ward with breast, lung, and colorectal cancer in Buenos Aires, Argentina. Arch Osteoporosis 11:4
9. Zhou W, Heist RS, Liu G et al (2007) Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol 25:479–485
10. Liu Y, Chen W, Hu Z-B et al (2011) Plasma vitamin D levels and vitamin D receptor polymorphisms are associated with survival of non-small cell lung cancer. Chin J Cancer Res 23:33–37
11. Ma K, Xu W, Wang C, Li B, Su K, Li W (2017) Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy. Cancer Biomark 18:297–303
12. Heist RS, Zhou W, Wang Z et al (2008) Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. J Clin Oncol 26:5596–5602
13. Vashi PG, Edwin P, Popiel B, Gupta D (2015) The relationship between circulating 25-hydroxyvitamin D and survival in newly diagnosed advanced non-small-cell lung cancer. BMC Cancer 15:1012
14. Holick MF (2017) The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord 18:153–165
15. Tsuprykov O, Chen X, Hocher C-F, Skoblo R, Lianghong Y, Hocher B (2018) Why should we measure free 25(OH) vitamin D? J Steroid Biochem Mol Biol 180:87–104
16. Powe CE, Evans MK, Wenger J et al (2013) Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 369:1991–2000
17. Yu C, Xue H, Wang L et al (2018) Serum bioavailable and free 25-hydroxyvitamin D levels, but not its total level, are associated with the risk of mortality in patients with coronary artery disease. Circul Res 123:996–1007
18. Bouillon R, Schuit F, Antonio L, Rastinejad F (2019) Vitamin D binding protein: a historic overview. Front Endocrinol 10:910
19. Yang J-R, Chen G-C, Xu J-Y et al (2019) Fasting blood glucose levels and prognosis in patients with non-small-cell lung cancer: a prospective cohort study in China. Onco Targets Ther 12:5947–5953
20. Holick MF, Binkley NC, Bischoff-Ferrari HA et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930
21. Li R, Wu J, Xiong L, Han B (2012) Lung cancer and benign lung diseases in patients with serious vitamin D deficiency in eastern China. Thoracic cancer 3:303–306
22. Liu N, Li X, Fu Y et al (2021) Inhibition of lung cancer by vitamin D depends on downregulation of histidine-rich calcium-binding protein. J Adv Res 29:13–22
23. Upadhyay SK, Verone A, Shoemaker S et al (2013) 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) signaling capacity and the epithelial-mesenchymal transition in non-small cell lung cancer (NSCLC): implications for use of 1,25(OH)2D3 in NSCLC treatment. Cancers 5:1504–1521
24. Mazzilli SA, Hershberger PA, Reid ME et al (2015) Vitamin D repletion reduces the progression of premalignant squamous lesions in the NTCU lung squamous cell carcinoma mouse model. Cancer Prev Res (Phila) 8:895–904
25. Verone-Boyle AR, Shoemaker S, Atrwood K et al (2016) Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo. Oncotarget 7:995–1013
26. Maj E, Filip-Psurska B, Milczarek M, Psurski M, Kutner A, Wietrzyk J (2018) Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model. Int J Oncol 52:337–366
27. Songyang Y, Song T, Shi Z, Li W, Yang S, Li D (2021) Effect of vitamin D on malignant behavior of non-small cell lung cancer cells. Gene 768:145309
28. Anic GM, Weinstein SJ, Mondul AM, Männistö S, Albanes D (2014) Serum vitamin D, vitamin D binding protein, and lung cancer survival. Lung Cancer (Amsterdam, Netherlands) 86:297–303
29. Chen P, Cao Y, Duan X, Li J, Zhao W, Wang H (2021) Bioavailable 25(OH)D level is associated with clinical outcomes of patients with diffuse large B-cell lymphoma: an exploratory study. Clin Nutr 40:157–165
30. Fang A-P, Long J-A, Zhang Y-J et al (2020) Serum bioavailable, rather than total, 25-hydroxyvitamin D levels are associated with hepatocellular carcinoma survival. Hepatology 72:169–182
31. Yuan C, Shui IM, Wilson KM, Stampfer MJ, Mucci LA, Giovannucci EL (2019) Circulating 25-hydroxyvitamin D, vitamin D binding protein and risk of advanced and lethal prostate cancer. Int J Cancer 144:2401–2407
32. Yuan C, Song M, Zhang Y et al (2020) Prediagnostic circulating concentrations of vitamin D binding protein and survival among patients with colorectal cancer. Cancer Epidemiol Biomark Prev 29:2323–2331
33. Gregory KJ, Zhao B, Bielenda DR et al (2010) Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS ONE 5:e13428
34. Thyer L, Ward E, Smith R et al (2013) A novel role for a major component of the vitamin D axis: vitamin D binding protein-derived macrophage activating factor induces human breast cancer cell apoptosis through stimulation of macrophages. Nutrients 5:2577–2589
35. Turner AM, McGowan L, Millen A et al (2013) Circulating DBP level and prognosis in operated lung cancer: an exploration of pathophysiology. Eur Respir J 41:410–416
36. Ko D-H, Jun S-H, Nam Y et al (2021) Multiplex LC-MS/MS for simultaneous determination of 25-hydroxyvitamin D, 24,25-dihydroxyvitamin D, albumin, and vitamin D-binding protein with its isoforms: one-step estimation of bioavailable vitamin D and vitamin D metabolite ratio. J Steroid Biochem Mol Biol 206:105796

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.